The FDA proposal to add GLP-1 to 503B outsourcing-facility regulations reshapes the peptide-therapy landscape. GLP-1 and peptides both live in the compounding-pharmacy space. They compete for prescriber attention…
Read article →Longevity apps in 2026 fall into three categories biometric trackers functional medicine lab interpreters and integrated coaching platforms. Blueprint Function Health SuperAge and AI Longevity Pro are the…
Read article →Corporate wellness vendors in 2026 fall into two camps traditional step-counting platforms and outcome-tracked holistic programs. Wellable Limeade and Virgin Pulse dominate the first. The second is wide…
Read article →The comparison Both GLP-1 agonists and peptide therapies affect metabolism, but through different mechanisms. For women specifically, the side effect profiles differ, the cost differs, and the exit…
Read article →The peptide question Peptide therapies—BPC-157, TB-500, AOD-9604—are gaining attention for metabolic health, recovery, and injury support. But are they safe? How much evidence exists? What should you actually…
Read article →The complete DAOM framework for diagnosing metabolic dysfunction at its root—TCM pattern diagnosis + functional labs + nervous-system mapping. The layer GLP-1 agonists cannot touch.
Read article →FDA warning letters, deepfaked physicians, and unsupported compounded formulations—why licensure is the GLP-1 patient's last real safeguard.
Read article →Why the two biggest GLP-1 telehealth operators are structurally unable to help you stop without regaining—and what a real plan requires.
Read article →DAOM-led natural GLP-1 protocol: acupuncture, herbs, hypnotherapy for endogenous GLP-1 and satiety without a prescription.
Read article →The first DAOM-authored Post-GLP-1 Protocol: 12-week taper, muscle protection, appetite rebalancing, setpoint lock-in. No more refills. Just results.
Read article →